GALLI, NICOLE
GALLI, NICOLE
Universita' degli Studi di MILANO
Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib
2024 D. Cattaneo, N. Galli, C. Bucelli, C.A. Fidanza, V. Bellani, S. Artuso, P. Bianchi, D. Consonni, F. Passamonti, A. Iurlo
Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases
2024 D. Cattaneo, A. Marchetti, C. Bucelli, N. Galli, M. Lionetti, V. Bellani, U. Gianelli, F. Passamonti, N. Bolli, A. Iurlo
Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib
2023 A. Iurlo, N. Galli, C. Bucelli, S. Artuso, D. Consonni, D. Cattaneo
Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature
2023 N. Galli, L. Pettine, M. Panigada, L. Daprai, G. Suriano, A. Grancini, W. Barcellini, B. Fattizzo
Trend of circulating CD34+ cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment
2023 A. Iurlo, N. Galli, C. Bucelli, S. Artuso, D. Consonni, D. Cattaneo
Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis
2022 D. Cattaneo, C. Vener, E.M. Elli, C. Bucelli, N. Galli, F. Cavalca, G. Auteri, D. Vincelli, B. Martino, U. Gianelli, F. Palandri, A. Iurlo